⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
globenewswire.com
NVO
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Andrew Ambrosy, Top Heart Doctor, Highlights GLP-1 and Dual GIP/GLP-1 Use for Lowering Risk of Cardiovascular Attack
prnewswire.com
NVO
LLY
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
globenewswire.com
NVO
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire.com
CLRS
MDT
PHG
BSX
BDX
BIOT
ABT
ANGI
RMAX
MRK
SNY
JNJ
BA
GSK
AZN
PFE
NVO
AMGN
VRTX
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
CYTK
NVO
BCDA
AZN
BMY
LLY
MESO
ASMB
LXRX
VTRS
AMGN
IRWD
NVS
MRK
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Following Reopened National Advertising Division Matter, Willow Health Services Voluntarily Discontinues Claims for Compounded Semaglutide Products
globenewswire.com
NVO
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
globenewswire.com
NVO
LLY